XL P53

Deletion Probe

Order Number
Package Size
100 µl


XL P53

This product has been replaced by XL TP53/17cen. Order Number D-5103-100-OG

Clinical Details

The prognosis and clinical course of CLL are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent in situ hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH abnormalities can be detected in more than 80 % of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10 % of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

TP53 is a tumor suppressor gene that stops cell division when DNA damage is present. Loss of TP53 at 17p13 is a powerful predictor of resistance to therapy with purine analogues and alkylating agents, and of poor prognosis in CLL.

The TP53 tumor suppressor gene is one of the most frequently mutated genes in human cancer with mutations and deletions identified in a wide range of solid tumors and hematological disorders.

Clinical Applications

  • Multiple Myeloma and Plasma Cell Neoplasms (MM)
  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myelogenous Leukemia (CML)


XL P53

XL P53 hybridized to lymphocytes. One normal interphase and metaphase are shown.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal resulting from loss of one orange locus.


  • Doehner et al (1995) Blood 85:1580-1589
  • Drach et al (1998) Blood 92:802-809
  • Doehner et al (2000) N Engl J Med 343:1910-1916


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.